Evaluation of the effect of melatonin in patients with Burning mouth syndrome
a double-blind, placebo-controlled randomized clinical trial
DOI:
https://doi.org/10.1590/s2175-97902023e21748%20Keywords:
Melatonin, BMS, SleepAbstract
The present study was carried out to evaluate the effect of Melatonin and Placebo in the patient
with the Burning mouth (BMs). This double-blind, placebo-controlled randomized clinical trial
study was carried out on 30 patients who were suffering from BMS. During this period patients
were divided into 2 study and control groups. The study group used four 3 mg Melatonin
daily and the control group received a placebo. Then the severity of the burning sensation was
measured by the physician Sleep quality was measured using the VAS scale using the Petersburg
questionnaire. Data in the application Enter SPSS 20 and then using T test or equivalent
Nonparametric was analyzed, mean sleep score and mean severity of oral irritation before and
after treatment in two the group was evaluated using T-test Independent. Level significance was
considered 0.05. The results of the present study show that the use of melatonin and a placebo
in patients with BMS reduces sensation and improves their sleep quality, although it may not
reduce it completely. In this study severity of burning was 4.93±2.56 after treatment in the study
group and 6.93±2.12 in the control group, which was statistically significant (P =0.036). No
significant difference was observed between the two groups in the sleep quality score (P-value
= 0.43). Using Melatonin can be a reliable way to treat pain for which there is no standard
treatment to date. Although evidence suggests an association between sleep disorders and
BMS, melatonin was not superior to a placebo in reducing BMS-induced burning in the present
study. Identification of stressors and the ways to struggle with them, further studies with larger
samples and higher oral doses, extended follow-up periods and control of psychological factors,
and measurement of body mass index that may affect pharmacokinetics are recommended
Downloads
References
Adamczyk-Sowa M, Pierzchala K, Sowa P, Mucha S, Sadowska-Bartosz I, Adamczyk J, et al. Melatonin acts as antioxidant and improves sleep in MS patients. Neurochem Res. 2014;39(8):1585-93.
Adamo D, Schiavone V, Aria M, Leuci S, Ruoppo E, Dell’Aversana G, et al. Sleep disturbance in patients with burning mouth syndrome: a case-control study. J Orofac Pain. 2013;27(4):304-13.
Almoznino G, Benoliel R, Sharav Y, Haviv Y. Sleep disorders and chronic craniofacial pain: Characteristics and management possibilities. Sleep Med Rev. 2017;33:39-50.
Amenabar JM, Pawlowski J, Hilgert JB, Hugo FN, Bandeira D, Lhuller F, et al. Anxiety and salivary cortisol levels in patients with burning mouth syndrome: case-control study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105(4):460-5.
Arbabi-Kalati F, Bakhshani N-M, Tahmtan B, Movahedinejad F. Association of impaired sleep quality in patients with burning mouth syndrome: A case-control study. Health Scope. 2015;4(2):e23795.
Arbabi-Kalati F, Tahmtan B. Evaluation of the effect of oral zinc sulfate on burning mouth syndrome: A Double blind randomized clinical trial. Dent Clin Exp J. 2015;1(1):e4601.
Boeve B. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Medicine. 2003;4(4):281-4.
Chainani-Wu N, Madden E, Silverman S, Jr. A case-control study of burning mouth syndrome and sleep dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod . 2011;112(2):203-8.
Cui Y, Xu H, Chen FM, Liu JL, Jiang L, Zhou Y, et al. Efficacy evaluation of clonazepam for symptom remission in burning mouth syndrome: a meta-analysis. Oral Dis. 2016;22(6):503-11.
Danilov A, Kurganova J. Melatonin in chronic pain syndromes. Pain Ther. 2016;5(1):1-17.
de Zanette SA, Vercelino R, Laste G, Rozisky JR, Schwertner A, Machado CB, et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacol Toxicol. 2014;15:40.
Eliav E. Altered structure and function in hippocampus and medial frontal cortex in patients with burning mouth syndrome. Pain. 2014;155(8):1424-5.
Farhad Molashahi L, Bakhshani N, Honarmand M, Shahri F, Teimuri S. Correlation between burning mouth syndrome and psychological symptoms in patients attending to zahedan dental school. SSU_Journals. 2012;20(2):187-93.
Hofmann SG, Asnaani A, Vonk IJJ, Sawyer AT, Fang A. The efficacy of cognitive behavioral therapy: A review of meta-analyses. Cognit Ther Res. 2012;36:427-440.
Imura H, Shimada M, Yamazaki Y, Sugimoto K. Characteristic changes of saliva and taste in burning mouth syndrome patients. J Oral Pathol Med. 2016;45(3):231-6.
Jehan S, Masters-Isarilov A, Salifu I, Zizi F, Jean-Louis G, Pandi-Perumal SR, et al. Sleep Disorders in Postmenopausal Women. J Sleep Disord Ther. 2015;4(5):212.
Kisely S, Forbes M, Sawyer E, Black E, Lalloo R. A systematic review of randomized trials for the treatment of burning mouth syndrome. J Psychosom Res. 2016;86:39-46.
Lee CF, Lin KY, Lin MC, Lin CL, Chang SN, Kao CH. Sleep disorders increase the risk of burning mouth syndrome: a retrospective population-based cohort study. Sleep Med. 2014;15(11):1405-10.
Lim JA, Choi SH, Lee WJ, Jang JH, Moon JY, Kim YC, et al. Cognitive-behavioral therapy for patients with chronic pain: Implications of gender differences in empathy. Medicine (Baltimore) 2018;97:e10867.
Lopez-Jornet P, Camacho-Alonso F, Lucero-Berdugo M. Quality of life in patients with burning mouth syndrome. J Oral Pathol Med . 2008;37(7):389-94.
Lopez-Jornet P, Lucero-Berdugo M, Castillo-Felipe C, Zamora Lavella C, Ferrandez-Pujante A, Pons-Fuster A. Assessment of self-reported sleep disturbance and psychological status in patients with burning mouth syndrome. J Eur Acad Dermatol Venereol. 2015;29(7):1285-90.
Lopez-Jornet P, Molino Pagan D, Andujar Mateos P, Rodriguez Agudo C, Pons-Fuster A. Circadian rhythms variation of pain in burning mouth syndrome. Geriatr Gerontol Int. 2015;15(4):490-5.
Martin S, Greenberg M, Glick M, Ship J. Burket’s oral medicine. Diagnosis and treatment 11th ed Hamilton: BC Decker. 2008:191-206.
McMillan R, Forssell H, Buchanan JA, Glenny AM, Weldon JC, Zakrzewska JM. Interventions for treating burning mouth syndrome. Cochrane Database Syst Rev. 2016;11(11):CD002779.
Nosratzehi T, Payandeh A, DehYadegari F. The complaints, type, and severity of stressful events in patients with burning mouth syndrome referring to zahedan school of dentistry, Iran. Clin Cosmet Investig Dent. 2020;12:123-30.
Reiter RJ, Rosales-Corral SA, Liu XY, Acuna-Castroviejo D, Escames G, Tan DX. Melatonin in the oral cavity: physiological and pathological implications. J Periodontal Res. 2015;50(1):9-17.
Scala A, Checchi L, Montevecchi M, Marini I, Giamberardino MA. Update on burning mouth syndrome: Overview and patient management. Crit Rev Oral Biol Med 2003;14:275-291.
Simcic D, Pezelj-Ribaric S, Grzic R, Horvat J, Brumini G, Muhvic-Urek M. Detection of salivary interleukin 2 and interleukin 6 in patients with burning mouth syndrome. Mediators Inflamm. 2006;2006(1):54632.
Sun A, Wu KM, Wang YP, Lin HP, Chen HM, Chiang CP. Burning mouth syndrome: a review and update. J Oral Pathol Med. 2013;42(9):649-55.
Varoni EM, Lo Faro AF, Lodi G, Carrassi A, Iriti M, Sardella A. Melatonin treatment in patients with burning mouth syndrome: a triple-blind, placebo-controlled, crossover randomized clinical trial. J Oral Facial Pain Headache. 2018;32(2):178-88.
Vidor LP, Torres IL, Custodio de Souza IC, Fregni F, Caumo W. Analgesic and sedative effects of melatonin in temporomandibular disorders: a double-blind, randomized, parallel-group, placebo-controlled study. J Pain Symptom Manage. 2013;46(3):422-32.
Zurowski D, Nowak L, Machowska A, Wordliczek J, Thor PJ. Exogenous melatonin abolishes mechanical allodynia but not thermal hyperalgesia in neuropathic pain. The role of the opioid system and benzodiazepine-gabaergic mechanism. J Physiol Pharmacol. 2012;63(6):641-7.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
